Sun Pharmaceutical has become the latest abbreviated new drug application sponsor to settle patent litigation with Bristol Myers Squibb’s Celgene over Revlimid (lenalidomide), adding to the litany of companies with a date-certain launch for the treatment for multiple myeloma.
The Indian firm’s settlement agreement comes soon after frontrunner Natco – which has partnered with Arrow and its parent Watson...




